Clinical Trials

CStone Pharmaceuticals announced that the National Medical Products Administration (NMPA) recently approved the clinical trial application (CTA) to start a Phase I clinical trial in China for BLU-554 (CS3008). An inhibitor of fibroblast growth factor receptor...

Bavarian Nordic A/S announced , that the first stage of a Phase 2 study of its novel, targeted cancer immunotherapy candidate, BN-Brachyury in the treatment of advanced chordoma has completed recruitment of the planned 10 patients ahead of schedule....

AbbVie , a research-based global biopharmaceutical company, announced the decision to stop enrollment for the TAHOE trial, a Phase 3 study evaluating Rovalpituzumab Tesirine (Rova-T) as a second-line therapy for advanced small-cell lung cancer (SCLC). An...

Reducing the costs associated with clinical trials is one of the pharmaceutical industry’s core challenges. Running a clinical trial is incredibly expensive and if a compound fails in the late phases, it can be catastrophic for its sponsor company. One...

Clinical oncology research is unique when compared to other therapeutic areas. Cancer patients experience substantial physical and psychosocial consequences of the disease and its treatment and much of the symptom burden occurs outside the clinical environment. Oncology research is uniquely...

AstraZeneca and MedImmune, its global biologics research and development arm, announced final overall survival (OS) results for the Phase III MYSTIC trial. A randomised, open-label, multi-centre, global trial of Imfinzi (durvalumab) monotherapy and the combination of...

Pharm-Olam, a global, midsized CRO offering full-service clinical development solutions for oncology, infectious diseases and vaccines, and rare and orphan diseases, extends its congratulations to Ablynx, a Sanofi company, for its launch of Cablivi® (caplacizumab) in the German market...